The key advantage of the system is the adaptor molecule, often an antibody-based reagent, that targets the TAA.
First-pass extracted concept
adaptor molecule
Candidate: concept label1 source documents6 linked claims
Live refresh every 5sNext refresh in 5s
Aliases
AM
Evidence Snippets
Supporting Sources
Linked Claims
Modular CAR T-cell effector function is activated only when the CAR, adaptor molecule, and antigen-positive target cell assemble correctly.
Quoted textsource-backed
Only when the CAR, AM, and antigen-positive target cell assemble correctly is T-cell effector function activated, leading to cancer cell lysis.
Adaptor molecules can be swapped or combined without re-engineering the T cells, enabling multiplexing and logic-gated control.
Quoted textsource-backed
Adaptors can be swapped or combined without re-engineering the T cells, enabling straightforward multiplexing and logic-gated control.
Adaptor architecture, especially size, affects pharmacokinetics and therefore adaptor dosing schemes in modular CAR systems.
Quoted textsource-backed
And lastly, the architecture of the AM, especially the size, defines the pharmacokinetics and, consequently, the dosing scheme of the AM.
Adaptor valency affects exhaustion and non-specific activation of modular CAR T cells.
Quoted textsource-backed
Third, the valency of the AM has an impact on exhaustion and non-specific activation of CAR T cells.
The affinities of CAR-adaptor and adaptor-antigen interactions mostly define engagement kinetics in modular CAR systems.
Quoted textsource-backed
Second, the affinity of CAR-AM and AM-TAA will mostly define the engagement kinetics of the system.
Modular CAR T cells use a two-part system in which the CAR binds an adaptor molecule and the adaptor binds the tumour-associated antigen.
Quoted textsource-backed
Modular CAR T cells use a two-part system: the CAR on the T cell binds an adaptor molecule (AM), and that adaptor binds the tumour-associated antigen (TAA).